Clinical Trials Act

Section 11: Trial licence

PART IVA: PUBLIC CLINICAL TRIAL UNIT AND NATIONAL CLINICAL TRIAL NETWORK

Clinical Trials ActSection 11

11. Trial licence (1) No person shall conduct or cause to be conducted a clinical trial unless – (a) a sponsor; Acts 2026 321 (b) the Public Clinical Trial Unit; or (c) an accredited principal investigator, holds a trial licence. (2) No person shall conduct or cause or permit to be conducted a clinical trial except in accordance with the terms and conditions of a trial licence. (3) Where a trial licence is held by an accredited principal investigator, the accredited principal investigator shall be responsible for ensuring that the clinical trial is conducted in accordance with this Act, any regulations made under it, the conditions of the trial licence and the principles of Good Clinical Practice. (4) Every clinical trial shall be conducted under the supervision of an investigator approved by the Council. (5) For the purposes of this Act, unless the context otherwise requires, every reference to a sponsor includes a trial licence holder who is not a sponsor, and the obligations imposed on a sponsor, including those under sections 22, 23, 24, 25, 27 and 28, shall apply accordingly to that trial licence holder. (h) in section 12 – (i) by repealing subsection (1) and replacing it by the following subsection – (1) A person eligible to hold a trial licence under section 11(1) who wishes to obtain a trial licence shall submit an application concurrently to the Council and the Ethics Committee through NELS or such other system as the Council may approve. (ii) in subsection (3), by deleting the words “The sponsor” and replacing them by the words “The applicant”; 322 Acts 2026 (iii) by repealing subsection (4) and replacing it by the following subsection – (4) On receipt of an application under subsection (1), the Council and the Ethics Committee shall review the application concurrently and may request from the applicant such additional documents or information as they may consider necessary for the determination of the application. (iv) by adding the following new subsections – (5) Where the Council and the Ethics Committee require additional documents or information, they shall, where reasonably practicable, issue a consolidated request to the applicant. (6) A request for additional documents or information shall suspend the applicable review period until the requested documents or information are received. (i) in section 13 – (i) in subsection (1), in paragraph (f), by deleting the words “the sponsor and the investigator” and replacing them by the words “the trial licence holder or the sponsor and the investigator”; (ii) in subsection (2), by deleting the word “sponsor” and replacing it by the word “applicant”; (iii) by repealing subsection (3) and replacing it by the following subsection – (3) On granting an application under subsection (1), the Council shall issue a trial licence to – (a) a sponsor; (b) the Public Clinical Trial Unit; or Acts 2026 323 (c) an accredited principal investigator, on such terms and conditions as it thinks fit and, subject to section 34A, on payment of such licence fee as may be prescribed. (j) by inserting, after section 13, the following new section –

This section is inserted by The Economic and Financial Measures (Miscellaneous Provisions) Act 2026, section 8.

Came into operation on 13 August 2026 (Gazette date; the Act states no other date for this provision).

consolidated text (as at 2017, amended since). juris shows the text as it was consolidated; it does not confirm that this is the law in force today.

Ask juris about this section Official source